m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02651)
Name
Rifaximin
Synonyms
Rifaximin; Rifaxidin; Rifacol; Xifaxan; Rifaximine; Rifamycin L 105; Rifamycin L 105SV; Rifaximina; Fatroximin; Normix; Rifaximinum; Rifamixin; Ritacol; Rifaximine [French]; Rifaximinum [Latin]; Rifaximina [Spanish]; Rifaximin [USAN:INN]; UNII-L36O5T016N; L 105SV; L 105 (Ansamacrolide antibiotic); L 105; C43H51N3O11; BRN 3584528; L36O5T016N; Rifaximin, 98%; Rifaximin (Xifaxan); MFCD00864973
    Click to Show/Hide
Status
Approved
Structure
3D MOL
2D MOL
Formula
C43H51N3O11
InChI
1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
InChIKey
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
PubChem CID
6436173
VARIDT Drug ID
DR00073
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifaximin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rifaximin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifaximin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rifaximin through regulating the expression of P-glycoprotein 1 (ABCB1). [2], [3]
References
Ref 1 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 2 Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813. doi: 10.1208/s12248-017-0052-1. Epub 2017 Feb 15.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.